US approves 1st drug developed to prevent chronic migraines
TRENTON, N.J. (AP) - U.S. regulators have approved the first drug designed to prevent chronic migraines.
Thursday's action by the Food and Drug Administration clears the monthly shot for sale. Aimovig is the first in a new class of long-acting drugs for preventing migraines. Three other shots are expected to win approval by next year, and several pills are being tested.
Current prevention treatments include pills originally developed for epilepsy and other conditions and the wrinkle reducer Botox, but many patients abandon them because they don't help much or cause serious side effects.
Migraines can cause disabling symptoms: throbbing headaches, nausea and vomiting, and sensitivity to light and sound.
Desktop NewsClick to open Continuous News in a sidebar that updates in real-time.
Tickets for Bayou Country Superfest on sale Thursday
IBM executive says company will keep its promise
13-year-old girl nearly kidnapped while walking to bus stop
Police: Man uses rock to break into seafood restaurant, steals crawfish
One dead, five rescued in early morning house fire on Elmer Ave.